Avadel Pharmaceuticals plc is a biopharmaceutical company dedicated to transforming medicines to improve patient lives, particularly focusing on the treatment of narcolepsy. Their flagship product, LUMRYZ, is the first and only once-at-bedtime oxybate approved by the FDA for managing cataplexy and excessive daytime sleepiness in patients aged 7 and older with narcolepsy. LUMRYZ contains sodium oxybate, a central nervous system depressant that requires careful management due to its potential for abuse and misuse, as well as significant risks of respiratory depression and other adverse effects. The company emphasizes the importance of a restricted distribution program, known as the LUMRYZ REMS, to ensure safe use and monitoring of patients prescribed this medication.

Avadel's approach to drug development is characterized by innovative solutions that address the challenges faced by patients with narcolepsy. The company is committed to understanding patient needs and enhancing the treatment experience through collaboration and a focus on meaningful outcomes. Their dedication to patient safety is evident in the stringent guidelines surrounding LUMRYZ, which include monitoring for potential psychiatric and behavioral reactions, as well as contraindications with other CNS depressants. By prioritizing patient experience and safety, Avadel aims to disrupt existing treatment paradigms and provide effective solutions for those affected by narcolepsy.

Ireland

We are a biopharmaceutical company passionately committed to providing solutions for overlooked and unmet medical needs through patient-focused, innovative products. 

Nervous System Diseases

Avadel Pharmaceuticals plc

Cataplexy

Excessive daytime sleepiness

Narcolepsy

<p class="font_7">FT218 is an investigational, once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate.&nbsp;</p>

Avadel Pharmaceuticals plc

Company Details